Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia's investors include Partners Investment, Innosuisse, GoBeyond, Foundation for Innovation and Technology (FIT), EISMEA.
Cellestia is headquartered in Basel, Switzerland.
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellestia — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/cellestia. Accessed November 13, 2026.
VCBacked. (2023). Cellestia — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/cellestia
{{cite web |title=Cellestia — Funding & Investors |url=https://www.vcbacked.co/company/cellestia |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cellestia? Request a listing update